DL Life Logo - - - - 121,159 AMERICANS ARE CANDIDATES ON THE UNOS TRANSPLANT WAIT LIST DL Life Logo 100,376 waiting for a kidney DL Life Logo 14,753 wait-listed for a liver DL Life Logo 1,029 waiting for a pancreasDL Life Logo 1,924 needing a Kidney-PancreasDL Life Logo 4,156 waiting for a life-saving heartDL Life Logo 1,469 waiting for a lungDL Life Logo 42 waiting for a heart-lungDL Life Logo 269 waiting for small bowelDL Life Logo One organ donor has the opportunity to save up to 8 lives DL Life Logo One tissue donor has the opportunity to save and -or enhance the lives of 50 or more individuals DL Life Logo An average of 22 people die everyday while waiting for a transplant. DL Life Logo You have the power to SAVE Lives by becoming an organ, eye and tissue donor, so what are you waiting for? To learn how to register click HEREDL Life Logo

Saturday, January 30, 2016

Sirolimus chemoprevention supported in organ transplant recipients

News Medical | Shreeya Nanda

In solid-organ transplant recipients (OTRs) diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.

They reviewed the electronic medical records of 329 patients who developed cancer a median of 42 months after undergoing solid-organ transplantation. Of these, 29.5% received the mammalian target of rapamycin (mTOR) inhibitor after diagnosis of the index cancer, while the remaining 70.5% did not.

Overall, 39.5% of study participants were diagnosed with a second post-transplant malignancy, at a median of 14 months after the index cancer, with the majority (88.5%) developing skin cancer, a known risk for OTRs.

A significantly smaller proportion of sirolimus-treated patients than those not treated developed a second post-transplant cancer, at 30.9% versus 43.1%, equating to a 12.2% decrease in the risk of a subsequent cancer of any type. Continue reading

 

No comments: